Jean M. Phelip
Saint-etienne-de-valoux, 42000, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study.
Journal: Clinics and research in hepatology and gastroenterology
Published: November 07, 2024
Reply to M. Salati et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 02, 2022
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 18, 2021
The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program-Results of a Survey on Daily Practice Patterns for Patients with mCRC.
Journal: Current oncology (Toronto, Ont.)
Published: May 20, 2021
Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
Journal: Alimentary pharmacology & therapeutics
Published: November 09, 2020
What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey.
Journal: World journal of surgery
Published: October 11, 2020
COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: March 23, 2020
Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?
Journal: Inflammatory bowel diseases
Published: November 29, 2017
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
Journal: Inflammatory bowel diseases
Published: September 26, 2017
Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Journal: Inflammatory bowel diseases
Published: December 22, 2016
Last Updated: 09/26/2026